Insider Selling: Cardlytics, Inc. (NASDAQ:CDLX) Insider Sells $23,722.88 in Stock

Cardlytics, Inc. (NASDAQ:CDLX) insider Nicholas Hollmeyer Lynton sold 6,464 shares of the company’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $3.67, for a total transaction of $23,722.88. Following the sale, the insider now directly owns 91,771 shares in the company, valued at $336,799.57. This trade represents a 6.58 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Cardlytics Trading Down 2.6 %

NASDAQ CDLX opened at $3.35 on Thursday. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 2.40. The stock’s 50-day simple moving average is $3.89 and its two-hundred day simple moving average is $4.77. Cardlytics, Inc. has a twelve month low of $2.89 and a twelve month high of $20.52. The company has a market capitalization of $170.25 million, a price-to-earnings ratio of -0.55 and a beta of 1.53.

Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.18. The company had revenue of $67.06 million for the quarter, compared to analysts’ expectations of $57.77 million. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. Cardlytics’s revenue for the quarter was down 15.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.26) EPS. Research analysts forecast that Cardlytics, Inc. will post -1.52 EPS for the current fiscal year.

Institutional Trading of Cardlytics

Several institutional investors have recently added to or reduced their stakes in the business. Atom Investors LP purchased a new position in shares of Cardlytics in the third quarter worth about $33,000. XTX Topco Ltd bought a new position in Cardlytics during the 2nd quarter worth approximately $107,000. SG Americas Securities LLC purchased a new position in Cardlytics in the 3rd quarter worth approximately $45,000. Intech Investment Management LLC bought a new stake in Cardlytics in the third quarter valued at approximately $47,000. Finally, Quest Partners LLC boosted its stake in shares of Cardlytics by 160.4% during the second quarter. Quest Partners LLC now owns 17,956 shares of the company’s stock valued at $147,000 after purchasing an additional 11,061 shares during the period. 68.10% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on CDLX shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Cardlytics in a report on Thursday, November 7th. Craig Hallum upgraded Cardlytics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. Finally, Evercore ISI started coverage on Cardlytics in a research report on Friday, October 11th. They set an “in-line” rating and a $4.00 price target for the company. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Cardlytics has a consensus rating of “Hold” and a consensus target price of $6.92.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.